Richard B. Lanman

Guardant Health to Report Second Quarter Financial Results on August 5, 2021

Retrieved on: 
Tuesday, July 13, 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021.
  • Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

Retrieved on: 
Tuesday, June 22, 2021

By broadening our Guardant360 portfolio to cover not only treatment selection but treatment response, we provide oncologists a more complete view of their patients tumor evolution and resistance to interventional therapies, including immunotherapies.

Key Points: 
  • By broadening our Guardant360 portfolio to cover not only treatment selection but treatment response, we provide oncologists a more complete view of their patients tumor evolution and resistance to interventional therapies, including immunotherapies.
  • The Guardant360 CDx test, the new Guardant360 TissueNext test, and the new Guardant360 Response test are all part of the Guardant360 portfolio, which provides oncologists a more complete genomic picture across the treatment journey.
  • From fast treatment selection, starting first with the FDA-approved Guardant360 CDx test, to reflex testing with the Guardant360 TissueNext test, if needed, to early treatment response monitoring with the Guardant360 Response test, the Guardant360 portfolio helps oncologists unlock the full potential of precision oncology for their patients with late-stage and metastatic cancers.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

Retrieved on: 
Tuesday, June 8, 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the companys new Chief Commercial Officer for its oncology business, effective June 8, 2021.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the companys new Chief Commercial Officer for its oncology business, effective June 8, 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210608005443/en/
    I am thrilled to welcome Chris Freeman as our new Chief Commercial Officer.
  • I am excited to join Guardant Health in their mission to improve cancer care for all patients, said Chris Freeman.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients.

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer

Retrieved on: 
Friday, June 4, 2021

Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer (CRC) in early-stage cancer patients.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer (CRC) in early-stage cancer patients.
  • Its great to see the momentum Guardant Health has achieved since the introduction of their best-in-class liquid biopsy technology in 2014.
  • Now, they are at the precipice of delivering a highly sensitive colorectal cancer screening test, and I look forward to seeing the outcome of their registrational study.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients.

Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer

Retrieved on: 
Thursday, April 1, 2021

Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patients status for residual disease, without the need for a tissue biopsy.

Key Points: 
  • Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patients status for residual disease, without the need for a tissue biopsy.
  • The Guardant Reveal blood test was introduced earlier this year and is Guardant Healths first commercially available liquid biopsy for clinical use in the management of early-stage cancer.
  • The incorporation of biologically relevant epigenomic signatures has been essential to increasing the sensitivity of the test to detect residual disease in early-stage cancers including CRC.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients.

Guardant Health to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 17, 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.
  • The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

Retrieved on: 
Thursday, February 4, 2021

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021.
  • Company management will be webcasting a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
  • The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients.

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe

Retrieved on: 
Monday, January 18, 2021

We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond, said Helmy Eltoukhy, Guardant Health CEO.

Key Points: 
  • We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond, said Helmy Eltoukhy, Guardant Health CEO.
  • We look forward to working together with Guardant Health to bring clinical-grade liquid biopsy genomic testing services to patients at pace and scale.
  • Guardant Healths liquid biopsy tests have been extensively used in clinical trials with over 200 peer-reviewed publications demonstrating its benefits to patients.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx and GuardantOMNI tests for advanced stage cancer patients.

Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer

Retrieved on: 
Thursday, January 14, 2021

The presentations will cover the use of Guardant Healths liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.

Key Points: 
  • The presentations will cover the use of Guardant Healths liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.
  • It is increasingly becoming evident that the value of our liquid biopsy in advanced cancer extends beyond simply tumor mutation profiling.
  • The data presented further demonstrates the value of assessing molecular response to treatment, ushering in a new age of adaptive management of disease progression, said Helmy Eltoukhy, Guardant Health CEO.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients.

Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 30, 2020

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.
  • Guardant Healths management is scheduled to present on Monday, January 11 at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time.
  • The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx and GuardantOMNI tests for advanced stage cancer patients.